FiercePharmaAsia—China’s $1.3B vaccine fine; Lantus biosim retreat; Taiho’s VC fund
admin 19th October 2018 Uncategorised 0China hands vaccine scandal culprit Changsheng a whopping $1.3 billion fine; Merck & Co. and Samsung Bioepis abandon development of a Lantus biosimilar on sales worries; Taiho injects another $250 million into its U.S.-based VC fund.
More: FiercePharmaAsia—China’s .3B vaccine fine; Lantus biosim retreat; Taiho’s VC fund
Source: fierce